page 1
page 2
page 3
page 4
page 5
page 6
page 7
page 8
page 9
page 10
page 11
page 12
page 13
page 14
page 15
page 16
page 17
page 18
page 19
page 20
page 21
page 22
page 23
page 24
page 25
page 26
page 27
page 28
page 29
page 30
page 31
page 32
page 33
page 34
page 35
page 36
page 37
page 38
page 39
page 40
page 41
page 42
page 43
page 44
page 45
page 46
page 47
page 48
page 49
page 50
page 51
page 52
page 53
page 54
page 55
page 56
page 57
page 58
page 59
page 60
page 61
page 62
page 63
page 64
page 65
page 66
page 67
page 68
page 69
page 70
page 71
page 72
page 73
page 74
page 75
page 76
page 77
page 78
page 79
page 80
page 81
page 82
page 83
page 84
page 85
page 86
page 87
page 88
page 89
page 90
page 91
page 92
page 93
page 94
page 95
page 96
page 97
page 98
page 99
page 100
page 101
page 102
page 103
page 104
page 105
page 106
page 107
page 108
page 109
page 110
page 111
page 112
page 113
page 114
page 115
page 116
page 117
page 118
page 119
page 120
page 121
page 122
page 123
page 124
page 125
page 126
page 127
page 128
page 129
page 130
page 131
page 132
page 133
page 134
page 135
page 136
page 137
page 138
page 139
page 140
page 141
page 142
page 143
page 144
page 145
page 146
page 147
page 148
page 149
page 150
page 151
page 152
page 153
page 154
page 155
page 156
page 157
page 158
page 159
page 160
page 161
page 162
page 163
page 164
page 165
page 166
page 167
page 168
page 169
page 170
page 171
page 172
page 173
page 174
page 175
page 176
page 177
page 178
page 179
page 180
page 181
page 182
page 183
page 184
page 185
page 186

58INNOVATION UK adoption of new technologies and regulations. » » The Bioscience Innovation and Growth Team ( BIGT), Bioscience 2015 report, recommendation 4 outlined a need to establish a strong bioprocessing subsector within UK bioscience. The recent 2009 review and refresh of thisreport have recommended that there be continued support to deliver the bioprocessing agenda original set out. » » National Institute for Health Research Medical Devices Clinical Research Working Group - ensuring the UK environment for clinical investigations for medical devices is attractive to UK and overseas businesses. » » NHS National Innovation Centre - defining un- met clinical need to stimulate demand- led innovation and supporting proof- of- concept projects. » » Joint government Small Business Research Initiative ( SBRI) - the TSB and Department of Health have launched a new programme to stimulate innovation in key clinical areas, covering such topics as hospital-acquired infections. Operationally, the HealthTech & Medicines KTN is active in the following: » » Special Interest Groups ( SIGs) in key clinical or issue-led topics such as Advanced Wound Management, Assistive Technologies, Clinical Trials, Drug Delivery, Orthopaedics, Regenerative Medicine, Biopharmaceutical Formulation, Bioprocessing Advance Therapies and Operational Excellence. These bring interested parties together, across government, industry, academia and the clinical base, to identify issues and opportunities, leading to new partnerships. » » Statement of Clinical Need ( SOCN) - a key part of the innovation cycle is ensuring that technologies are developed that meet a clear clinical need. » » Events - working in collaboration with other KTNs, professional institutions, trade associations and commercial organisations, an annual programme of events ( physical and online) is run to ensure different parts of the community can meet and develop new areas of collaboration or make the right connections to speed up current developments. » » Portal - as with all KTNs there is an active portal which enables share of information and knowledge, as well as tools to share confidential and non-confidential documents, and to run online open and private meetings with colleagues anywhere in the world - www. healthtechktn. com and www. bioprocessuk. org. » » Access to finance - innovation requires finance from the earliest stage to prototyping and initial manufacture and trials. The KTN advises on the various public grant schemes, public contracts and contacts into private venture for later- stage developments. In particular, the KTN supports programmes funded by the Technology Strategy Board ( Collaborative R& D, Innovation Platforms) and the National Institute for Health Research ( Invention of Innovation ( i4i)). For more information, contact: Dr Tony Bradshaw, Co- Director HealthTech & Medicines Knowledge Transfer Network E- mail: bioprocessuk@ bioindustry. org Tel: + 44 ( 0) 20 75657143 Website: www. bioprocessuk. org Sue Dunkerton, Co- Director HealthTech & Medicines Knowledge Transfer Network E- mail: healthtechktn@ twi. co. uk Tel: + 44 ( 0) 1223 899000 Website: www. healthtechktn. com The National Institute for Health Research ( NIHR), Invention for inovation ( i4i) Programme Launched in July 2008, i4i combines two pre- existing Department of Health product development pro-grammes, New and Emerging Applications of Technol-ogy and Health Technology Devices, with additional new funding. This provides new investment to improve the identification of promising healthcare technologies and to accelerate the development of new healthcare products for the 21st century. The KTN supports the NIHR with the i4i programme to support the develop-ment of innovative products so that they are available for procurement by the NHS. The i4i programme funds translational research, extending between basic research and pre- clinical trials or health technology assessments. Activities include: » » Future Product Development ( FPD) - FPD is the main funding activity of i4i and is positioned at the " upstream" part of the innovation process - that is close to " ideas generators". » » Pilot Healthcare Technology Co- operatives ( HTCs) - Based in two NHS Trusts, the pilot HTCs are a new type of NHS- led virtual organisation which bring together a wide spectrum of stakeholders with a common purpose. These include patients, carers, academics, clinicians, nurses and other healthcare providers working in partnership with industry to catalyse the development of innovative healthcare technology products. » » Small Business Research Initiative ( SBRI) - The SBRI funding stream complements FPD. Under SBRI, companies respond to a requirements specification provided by i4i. The aim of the SBRI programme is to provide a route where NHS needs can be met directly. For more information, visit: www. nihr- ccf. org. uk/ site/ programmes/ i4i HealthTech & Medicines Knowledge Transfer Network Healthcare healthtech & medicines ktn

INNOVATION UK59 Improving the health and wealth of the nation through research Every patient deserves access to the best possible evidence- based health and social care. The National Institute for Health Research ( NIHR) was set up in 2006 to build the world- class health research system needed to deliver high- quality research and innovation across the NHS. The NIHR's 12 Biomedical Research Centres ( BRCs) are successfully turning laboratory- based discoveries into cutting- edge new treatments, diagnostic tools and other innovations. These include the world's first successful gene therapy for a rare, inherited form of blindness, developed by a team from the BRC at the University College London ( UCL) Institute of Ophthalmology and Moorfields Eye Hospital. The NIHR BRCs are at the heart of all five Academic Health Science Centres ( AHSCs) announced in March 2009. These are partnerships between leading research-ers and frontline NHS staff to improve the transfer of pioneering new treatments into practice. " We are committed to establishing the NHS as an internationally recognised centre of research excel-lence - supporting outstanding individuals, working in world- class facilities, conducting leading- edge research focused on the needs of patients and the public." Professor Dame Sally C. Davies, Director General of Research and Development, Department of Health Revolutionising the treatment of type 1 diabetes Mathematician Dr Roman Hovorka, Principal Research Associate at the Cambridge Comprehensive BRC, is responsible for programming the sophisti-cated mathematical calculations needed to make an artificial pancreas work exactly like a real pancreas. He says: " Being part of a pool of experts at the BRC in Cam-bridge has enabled us to develop a prototype of an artificial pancreas to help people with type 1 diabetes, where the pancreas does not produce insulin needed by the body to control blood sugar. " If successful, this could reduce the need for repeated finger- prick blood tests and insulin injections, help-ing patients to avoid hypoglycaemia ( episodes of low blood sugar), as well as saving NHS costs. " The ' pancreas' consists of a subcutaneous sensor, which detects glucose levels continuously, feeding the results into a computer program that works out how much insulin is needed and delivers it via a small insulin pump. " So far, overnight clinic tests on over 30 children, adults and pregnant women with type 1 diabetes show that the system can control blood glucose bet-ter than standard treatment. We are now working on a home system, which we plan to evaluate in a small pilot." Healthcare national institute for health research